Prothena Corp PLC is a biotechnology company focuses on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
| Website: | www.prothena.com |
| Email: | info@prothena.com |
| Main Phone: | +353 12362500 |
| Address: | 77 Sir John Rogerson's Quay |
| Address 2: | Block C |
| City / Town: | Dublin |
| Country: | IRL |
| Postal Code: | D02 T804 |
| Exchange: | NGS |
| CEO: | Gene G. Kinney |
| Employees: | 51 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
$150 million upfront + up to $2.1 billion in milestone payments
Like the broader markets, the biotech indices reeled on the news of Britain's vote to exit the European Union.
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors,
Small-cap companies (that is, companies that are worth between $300 million and $2 billion) can be a risky investment, as smaller companies tend to have lower stock prices and thus are more
Prothena Corporation (PRTA) , the drug discovery business that was spun-out of Elan Corp. (ELN) in December last year, reported its financial results for the second quarter ended June 30 after
Prothena Corp PLC is a biotechnology company focuses on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
| Website: | www.prothena.com |
| Email: | info@prothena.com |
| Main Phone: | +353 12362500 |
| Address: | 77 Sir John Rogerson's Quay |
| Address 2: | Block C |
| City / Town: | Dublin |
| Country: | IRL |
| Postal Code: | D02 T804 |
| Exchange: | NGS |
| CEO: | Gene G. Kinney |
| Employees: | 51 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
$150 million upfront + up to $2.1 billion in milestone payments
Like the broader markets, the biotech indices reeled on the news of Britain's vote to exit the European Union.
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors,
Small-cap companies (that is, companies that are worth between $300 million and $2 billion) can be a risky investment, as smaller companies tend to have lower stock prices and thus are more
Prothena Corporation (PRTA) , the drug discovery business that was spun-out of Elan Corp. (ELN) in December last year, reported its financial results for the second quarter ended June 30 after
| Last Price 10.87 | Change $ 0.19 | Change % 1.78 | Tick N/A |
| Bid 10.78 | Bid Size 200.00 | Ask 10.92 | Ask Size 100.00 |
| Open 10.60 | High 11.07 | Low 10.60 | Prev Close 10.68 |
| Last Trade | Volume 53,773 | 52 Wk Hi 17.63 | 52 Wk Low 6.72 |
| Market Cap 433.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 39,911,413.00 | EPS (TTM) -2.02 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 26 |
| Number of Buys | 0 | 11 |
| Number of Sells | 0 | 15 |
| Net Activity | 0 | 0 |
| Last 10 Buys | Shares |
|---|---|
| Tran B. Nguyen | 1,000 |
| Dale Schenk | 1,000 |
| Dale Schenk | 1,000 |
| Tara Nickerson | 1,000 |
| Gene Kinney | 1,000 |
| Tran B. Nguyen | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Dennis J Selkoe | 1,000 |
| Dennis J Selkoe | 1,000 |
| Tara Nickerson | 1,000 |
| Wagner M. Zago | 1,000 |
| Karin L. Walker | 1,000 |
| Gene Kinney | 1,000 |
| Christopher S. Henney | 1,000 |
| Tara Nickerson | 1,000 |
| Tara Nickerson | 1,000 |
| Tara Nickerson | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 19 | 19 | 19 | 19 |
| Low Target Price Estimate | 11 | 11 | 11 | 11 |
| Mean Target Price Estimate | 13.67 | 13.67 | 13.67 | 13.67 |
| Standard Deviation | 2.29 | 2.29 | 2.29 | 2.29 |
| Date of Most Recent Estimate | 05/21/18 | 05/21/18 | 05/21/18 | 05/21/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-05-25 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 8-K | Report of unscheduled material events or corporate changes. | 21 | 2018-05-18 |
| SC 13G/A | Amendment to the SC 13G filing | 1 | 2018-05-10 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 421 | 2018-05-09 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 3 | 8 | 7 |
| Moderate Buy | 0 | 0 | 1 | 1 |
| Hold | 6 | 6 | 1 | 1 |
| Moderate Sell | 1 | 1 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 |
| Mean Rec. | 2.9 | 2.5 | 1.3 | 1.33 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait